Axonal degeneration and neuroinflammation are critical processes involved in various neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and glaucoma. Recent research has ...
The Massachusetts based biotech will now press ahead with human trials for its antisense oligonucleotide (ASO) therapy, ...
GlobalData on MSN15d
FDA lifts clinical hold on Amylyx’s Phase I ALS trialAmylyx will be allowed to run a Phase I trial after the FDA lifted a clinical hold of its investigational ALS drug.
Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of ALS ...
CAMBRIDGE, Mass. - Amylyx Pharmaceuticals Inc. (NASDAQ: AMLX), a $245.1 million market cap biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical ...
Axonotmesis indicates a loss of axon continuity, though the endoneural tube is preserved. This structural injury results in wallerian degeneration. Severe crush or traction injuries can produce ...
The most severe injuries have been associated with widespread axonal and myelin degeneration (Gentili, Hudson, and Hunter, 1980a). Pathological alterations in the nerve were evident as early as 30 ...
With the hold lifted, Amylyx can begin screening and enrolling for its Phase 1 LUMINA trial, which will test AMX0114 in ALS ...
Previous research has established that, when a peripheral neuron’s axon is severed, it decreases its synthesis ... Using two mutant murine strains (the slow Wallerian degeneration mouse and a knockout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback